Systematic comparison of four cell- and luminex-based methods for assessment of complement-activating HLA antibodies

Transplantation

Volumn 95, Issue 5, 2013, Pages 694-700

  Lachmann, Nils ^a   Todorova, Kremena ^a   Schulze, Harald ^a   Schönemann, Constanze ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

C1q; C4d; HLA antibody; Kidney transplantation

Indexed keywords

COMPLEMENT COMPONENT C1Q ANTIBODY; COMPLEMENT COMPONENT C4D; HLA ANTIBODY; HLA ANTIGEN CLASS 1; HLA ANTIGEN CLASS 2; IMMUNOGLOBULIN G ANTIBODY; ALLOANTIBODY; COMPLEMENT; COMPLEMENT C4D; COMPLEMENT COMPONENT C1Q; COMPLEMENT COMPONENT C4B; HLA ANTIGEN; PEPTIDE FRAGMENT;

ANTIBODY DETECTION; ANTIBODY SPECIFICITY; ARTICLE; COMPLEMENT ACTIVATION; COMPLEMENT DEPENDENT CYTOTOXICITY; COMPLEMENT DEPENDENT LYMPHOCYTOTOXICITY; COMPLEMENT FIXATION; FLUORESCENCE ANALYSIS; HUMAN; IMMUNOASSAY; INTERMETHOD COMPARISON; KIDNEY TRANSPLANTATION; OVERALL SURVIVAL; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; BLOOD; COMPARATIVE STUDY; CYTOTOXICITY; IMMUNIZATION; IMMUNOLOGY; METHODOLOGY;

COMPLEMENT C1Q; COMPLEMENT C4B; COMPLEMENT SYSTEM PROTEINS; CYTOTOXICITY, IMMUNOLOGIC; HLA ANTIGENS; HUMANS; IMMUNIZATION; IMMUNOASSAY; ISOANTIBODIES; PEPTIDE FRAGMENTS;

MLCS; MLOWN;

EID: 84877274007     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e31827b3dc3     Document Type: Article

References (25)

1. Patel R, Terasaki PI. Significance of the positive crossmatch test in kidney transplantation. N Engl J Med 1969; 280: 735.
2. Buelow R, Mercier I, Glanville L, et al. Detection of panel-reactive anti-HLA class I antibodies by enzyme-linked immunosorbent assay or lymphocytotoxicity. Results of a blinded, controlled multicenter study. Hum Immunol 1995; 44: 1.
3. Schonemann C, Groth J, Leverenz S, et al. HLA class I and class II antibodies: monitoring before and after kidney transplantation and their clinical relevance. Transplantation 1998; 65: 1519.
4. Pei R, Lee J, Chen T, et al. Flow cytometric detection of HLA antibodies using a spectrum of microbeads. Hum Immunol 1999; 60: 1293.
5. Lefaucheur C, Suberbielle-Boissel C, Hill GS, et al. Clinical relevance of preformed HLA donor-specific antibodies in kidney transplantation. Am J Transplant 2008; 8: 324.
6. Susal C, Ovens J, Mahmoud K, et al. No association of kidney graft loss with human leukocyte antigen antibodies detected exclusively by sensitive Luminex single-antigen testing: a Collaborative Transplant Study report. Transplantation 2011; 91: 883.
7. Feucht HE, Schneeberger H, Hillebrand G, et al. Capillary deposition of C4d complement fragment and early renal graft loss. Kidney Int 1993; 43: 1333.
8. Platt JL. C4d and the fate of organ allografts. J Am Soc Nephrol 2002; 13: 2417.
9. Racusen LC, Halloran PF, Solez K. Banff 2003 meeting report: new diagnostic insights and standards. Am J Transplant 2004; 4: 1562.
10. Wahrmann M, Exner M, Haidbauer B, et al. [C4d]FlowPRA screeningV a specific assay for selective detection of complement-activating anti-HLA alloantibodies. Hum Immunol 2005; 66: 526.
11. Smith JD, Hamour IM, Banner NR, et al. C4d fixing, luminex binding antibodiesVa new tool for prediction of graft failure after heart transplantation. Am J Transplant 2007; 7: 2809.
12. Chin C, Chen G, Sequeria F, et al. Clinical usefulness of a novel C1q assay to detect immunoglobulin G antibodies capable of fixing complement in sensitized pediatric heart transplant patients. J Heart Lung Transplant 2011; 30: 158.
13. Rose ML, Smith JD. Clinical relevance of complement-fixing antibodies in cardiac transplantation. Hum Immunol 2009; 70: 605.
14. Wahrmann M, Bartel G, Exner M, et al. Clinical relevance of preformed C4d-fixing and non-C4d-fixing HLA single antigen reactivity in renal allograft recipients. Tr a n s p l I n t 2009; 22: 982.
15. Bartel G, Wahrmann M, Exner M, et al. In vitro detection of C4d-fixing HLA alloantibodies: associations with capillary C4d deposition in kidney allografts. Am J Transplant 2008; 8: 41.
16. Murata K, Baldwin WM 3rd. Mechanisms of complement activation, C4d deposition, and their contribution to the pathogenesis of antibody-mediated rejection. Transplant Rev (Orlando) 2009; 23: 139.
17. Chen G, Sequeira F, Tyan DB. Novel C1q assay reveals a clinically relevant subset of human leukocyte antigen antibodies independent of immunoglobulin G strength on single antigen beads. Hum Immunol 2011; 72: 849.
18. Tait BD, Hudson F, Cantwell L, et al. Review article: Luminex technology for HLA antibody detection in organ transplantation. Nephrology (Carlton) 2009; 14: 247.
19. Minucci PB, Grimaldi V, Casamassimi A, et al. Methodologies for anti-HLA antibody screening in patients awaiting kidney transplant: a comparative study. Exp Clin Transplant 2011; 9: 381.
20. Otten HG, Verhaar MC, Borst HP, et al. Pretransplant donor-specific HLA class-I and-II antibodies are associated with an increased risk for kidney graft failure. Am J Transplant 2012; 12: 1618.
21. Taylor CJ, Kosmoliaptsis V, Summers DM, et al. Back to the future: application of contemporary technology to long-standing questions about the clinical relevance of human leukocyte antigen-specific allo-antibodies in renal transplantation. Hum Immunol 2009; 70: 563.
22. Bohmig GA, Bartel G, Wahrmann M. Antibodies, isotypes and complement in allograft rejection. Curr Opin Organ Transplant 2008; 13: 411.
23. Schnaidt M, Weinstock C, Jurisic M, et al. HLA antibody specification using single-antigen beadsVa technical solution for the prozone effect. Transplantation 2011; 92: 510.
24. Akiyoshi T, Hirohashi T, Alessandrini A, et al. Role of complement and NK cells in antibody mediated rejection. Hum Immunol 2012; 73: 1226.
25. Terasaki PI, McClelland JD. Microdroplet assay of human serum cytotoxins. Nature 1964; 204: 998.